Objetivo Peripheral Nerve Injuries (PNIs) are lesions of the nerves of the head or the extremities. Grand View Research estimates over 2 million cases of PNIs per year in the EU and the USA. These injuries remain incurable, resulting in permanent loss of body function as in paraplegia, leading to disabilities and heavy social burden. The chance to cure PNIs based on smart nano-engineered biomaterials will have a major positive impact in heavy and long term burdens on patients and healthcare systems. In this context, Nerve Biomed’s team, a spin-off company of the Polytechnic University of Valencia (Spain) has been leading an R&D initiative in advanced PNI reparation over the past 11 years, in order to develop and further commercialise ULTRANERVE: an easy-to-use medical solution for PNI regeneration, which is going to simplify medical procedures and reduce the average full recovery time, while decreasing significantly the average cost of actual repair procedures.Within the roadmap established by the company to commercialize the product internationally by 2020, Nerve Biomed wants to perform a thorough feasibility study, through this SME Instrument Phase 1, which will assess in detail the practical and economic viability of introducing this solution in the PNI repair and regeneration market ih the EU and the USA. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinephysiotherapymedical and health sciencesmedical biotechnologynanomedicinemedical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicineneurology Programa(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Tema(s) SMEInst-02-2016-2017 - Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs Convocatoria de propuestas H2020-SMEInst-2016-2017 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-1-2016-2017 Régimen de financiación SME-1 - SME instrument phase 1 Coordinador NERVE BIOMED SOCIEDAD LIMITADA Aportación neta de la UEn € 50 000,00 Dirección CALLE CANONIGO MOLINA ALONSO, NUM. 6 04004 ALMERIA España Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región Sur Andalucía Almería Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 71 429,00
